InterMune Company Profile (NASDAQ:ITMN)

Analyst Ratings

Consensus Ratings for InterMune (NASDAQ:ITMN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for InterMune (NASDAQ:ITMN)
Show:
DateFirmActionRatingPrice TargetActions
8/29/2014Royal Bank Of CanadaBoost Price Target$44.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2014Cowen and CompanyInitiated CoverageMarket Perform$74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2014JPMorgan Chase & Co.DowngradeOverweight -> Neutral$74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Jefferies GroupUpgradeUnderperform -> Hold$25.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014William BlairBoost Price Target$55.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Stifel NicolausDowngradeBuy -> Hold$53.80 -> $53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Leerink SwannBoost Price Target$53.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Robert W. BairdBoost Price TargetOutperform$50.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2014Goldman Sachs Group Inc.DowngradeBuy -> Neutral$52.06 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for InterMune (NASDAQ:ITMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013Q313($0.71)($0.61)$16.44 million$19.72 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2012$0.10$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2011$0.64$3.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for InterMune (NASDAQ:ITMN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for InterMune (NASDAQ:ITMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Sean NolanVPSell2,644$35.85$94,787.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Social

About InterMune

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ITMN
  • CUSIP: 45884X10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $0
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-2.74 EPS
  • Next Year EPS Consensus Estimate: $-1.33 EPS
Additional Links:
InterMune (NASDAQ:ITMN) Chart for Monday, July, 25, 2016